Allergan PLC completed the acquisition of ZELTIQ Aesthetics Inc. for $2.47 billion in cash.

The deal was approved by the ZELTIQ shareholders at a special meeting held April 27.

Under the deal, each share of the ZELTIQ common stock issued and outstanding immediately before the deal completion was canceled and converted into the right to receive $56.50 in cash, without interest and subject to any applicable withholding of taxes.

Mark Foley, CEO and president; Taylor Harris, CFO and senior vice president; Todd Zavodnick, president of International; and Sergio Garcia, senior vice president, general counsel and corporate secretary, ceased to be ZELTIQ's officers, effective April 28.

Foley, David Endicott, Kevin O'Boyle, D. Keith Grossman, Mary Fisher and Andrew Schiff ceased to serve as directors of ZELTIQ.

Sigurd Kirk and Kira Schwartz will be joining the board of the surviving company.